About this trial
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
Within the prospective study, biological specimens from patients undergoing in-room biopsy before RT, will be collected. Histological evaluation and cell culture (and organoid preparation) will be conducted, and samples/organoids will be irradiated with RT for biological validation.
Eligibility criteria
Qualifiers
Unifocal infiltrating ductal breast carcinoma, non-special histotype
clinical stage T1-T2,N0
No contraindications to MRI, or metal joint prostheses from knee to shoulder included, or femoral stent.
Patients aged >18 years
Disqualifiers
Nodule involvement and metastasis (cN1 and/or cM1)
Concomitant inflammation of the intestine
Significant systemic diseases or ongoing oral anticoagulant therapy
Non-compliance of dose constraints in the treatment plan
Trial design
Treatments tested in this trial
- prostate patient
- breast patients